On March 28, 2020, Aadi Bioscience, Inc. (NASDAQ:AADI) announced that it has entered into an agreement to pay a $72.5 million settlement to settle a pending litigation action brought by the U.S. Attorney's Office for the Southern District of New York.  The settlement is subject to court approval.  According to the SEC's complaint filed in federal court in Tampa, Florida, Aadi had some difficulty recruiting patients for its early-stage trial in ovarian cancer.  The SEC's complaint, filed in federal court in Orlando, Florida, alleges that Aadi had difficulty recruiting patients for its early-stage trial.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, alleges that Aadi had difficulty recruiting patients.  The SEC's complaint charges Aadi with violating Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Aadi has agreed to pay a $72.5 million settlement, which is subject to court approval.Â  The settlement is subject to court approval.  The SEC's investigation was conducted by Scott Giacobello, Neil Desai, and Ahu Demir, and was supervised by Scott Giacobello.  The litigation will be led by Mr. Giacobello and Ms. Graham.  The SEC appreciates the assistance of the U.S. Attorney's Office for New York and the Federal Bureau of Investigation.  The SEC's Office of Inspector General has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the SEC'sÂ Investor.gov website.